ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
13.21
+0.23 (1.77%)
Real-time:   1:30PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.16 - 13.65
52 week 5.34 - 19.43
Open 13.25
Vol / Avg. 478,283.00/1.18M
Mkt cap 1.11B
P/E     -
Div/yield     -
EPS -0.71
Shares 86.96M
Beta 1.54
Inst. own 92%
Nov 11, 2015
Immunogen Inc Annual Shareholders Meeting (Estimated) - 11:00AM EST - Add to calendar
Oct 22, 2015
Q1 2016 ImmunoGen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 18, 2015
ImmunoGen Inc Analyst and Investor Event - 8:30AM EDT - Add to calendar
Sep 16, 2015
ImmunoGen Inc at Morgan Stanley Healthcare Conference - 2:50PM EDT - Add to calendar
Aug 12, 2015
ImmunoGen Inc at Canaccord Genuity Growth Conference
Jul 31, 2015
Q4 2015 ImmunoGen Inc Earnings Release
Jul 31, 2015
Q4 2015 ImmunoGen Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -241.65% -71.01%
Operating margin -198.93% -63.66%
EBITD margin - -57.21%
Return on average assets -54.61% -25.35%
Return on average equity -257.94% -109.63%
Employees 317 -
CDP Score - -

Address

830 WINTER ST
WALTHAM, MA 02451-1477
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoGen, Inc. is a biotechnology company. The Company develops targeted anticancer therapeutics. The Company has three wholly-owned product candidates in clinical testing, with seven additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. The Company’s clinical-stage product candidates, include IMGN289, IMGN853 and IMGN529. IMGN289 compound is a treatment for many cases of head and neck cancers. IMGN853 compound is a potential treatment for epithelial ovarian cancer, endometrial cancer and other cancers. IMGN529 compound is used for the treatment of NHL (non-Hodgkin lymphoma). The Company’s IMGN529 ADC is a new treatment for cancers that express CD37, such as NHL and chronic lymphocytic leukemia.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Daniel M. Junius President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Age: 59
Bio & Compensation  - Reuters
Richard J Gregory Ph.D. Executive Vice President - Research, Chief Scientific Officer
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Distinguished Research Fellow
Age: 63
Bio & Compensation  - Reuters
Sandra E. Poole Senior Vice President - Technical Operations.
Age: 51
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
Anna Berkenblit M.D. Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Peter J. Williams Vice President - Business Development
Age: 60
Bio & Compensation  - Reuters
Mark A. Goldberg M.D. Independent Director
Age: 54
Bio & Compensation  - Reuters